Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 380Brain Neoplasms 376Glioma 232Gliosarcoma 147Astrocytoma 138Neuroblastoma 121Central Nervous System Neoplasms 118Oligodendroglioma 80Medulloblastoma 61Breast Neoplasms 52Neoplasms 51Melanoma 45Ependymoma 43Carcinoma, Non-Small-Cell Lung 42Recurrence 40Sarcoma 33Meningioma 33Rhabdomyosarcoma 32Osteosarcoma 31Neurofibromatosis 1 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 27Wilms Tumor 26Lung Neoplasms 26Neuroectodermal Tumors, Primitive, Peripheral 25Sarcoma, Ewing 23Lymphoma 22Rhabdoid Tumor 20Hepatoblastoma 19Testicular Neoplasms 17

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Tuberous Sclerosis 2 × CNS × Clear all
NCT00790400 2017-02-17

EXIST-2

Novartis

Phase 3 Completed
118 enrolled 15 charts
CNS

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡